Form 4: Quince Therapeutics Director Rajiv Patni Acquires Stock Options
SEC Form 4 Filing
Director Rajiv Patni acquired stock options for 13,500 shares of Quince Therapeutics, Inc. at an exercise price of $0.82 on June 5, 2024.
Summary
- On June 5, 2024, Rajiv Patni, a director of Quince Therapeutics, Inc., acquired stock options for 13,500 shares.
- The exercise price for these options is $0.82 per share.
- The options vest 100% on the one-year anniversary of the grant date, June 5, 2025.
- The options expire on June 5, 2034.
- Following the transaction, Patni directly owns 13,500 derivative securities.
Sentiment
Score: 6
Explanation: Neutral sentiment as it's a standard disclosure of stock option grants. The acquisition by a director can be seen as a slightly positive sign, but it's not a major event.
Positives
- The acquisition of stock options by a director signals confidence in the company's future prospects.
Industry Context
Form 4 filings are standard disclosures required by the SEC when insiders, such as directors and officers, trade in their company's stock. This provides transparency to the market.
Stakeholder Impact
- The transaction provides transparency to shareholders regarding insider activity.
Key Dates
| Date | Description |
|---|---|
| 06/05/2024 | Date of transaction: Rajiv Patni acquired stock options. |
| 06/05/2025 | Vesting date: 100% of the stock options vest. |
| 06/05/2034 | Expiration date: Stock options expire. |
| 06/07/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.